Kyverna Therapeutics chose James Chung, M.D., Ph.D., as the cell therapy company’s first chief medical officer.

Erin Pennock Foff, M.D., Ph.D., was named chief medical officer of the CNS company MapLight Therapeutics.

LogicBio Therapeutics Inc., a clinical-stage genetic medicine company, promoted Daniel Gruskin, M.D., to chief medical officer.

Capsida Biotherapeutics Inc. appointed Swati Tole, M.D., as the biotechnology company’s first chief medical officer.

Shaemus Gleason was appointed executive VP U.S. operations at Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease.

Irena Melnikova, Ph.D., was hired by Umoja Biopharma to be the biotechnology company’s new chief financial officer.

Robert M. Schinagl, Ph.D., a biotech industry veteran with more than 20 years of experience, was tapped as VP of program and alliance management at OncoSec Medical Inc.

Blueprint Medicines Corp. tapped Percy Carter, Ph.D., as chief scientific officer. In this role, Dr. Carter oversees all of the company’s research and preclinical development.

Tevard Biosciences, a privately held biotechnology company pioneering tRNA-based gene therapies for rare and severe genetic diseases, named Gopi Shanker, Ph.D., as chief scientific officer and as a member of the company’s executive leadership team.

Gracell Biotechnologies Inc. appointed Dr. Jenny (Yajin) Ni as the cancer cell therapy company’s chief technology officer.